Abstract:17Running Title 2 This is a provisional file, not the final typeset article analysis involving canine and human transcriptome data provided several genes with potential to be 36 markers for both human and canine bladder tumors and these genes should be considered for future 37 studies on canine bladder cancer. 38 39
“…Canine UC is known for its increased invasiveness at the time of diagnosis and is an important model for muscle-invasive diseases in humans ( 1 , 4 ). However, despite the difficulties associated with the treatment of this tumor type in dogs, most studies related to biomarkers for bladder UC in veterinary medicine analyze isolated molecules without assessing their prognostic value or association with other variables ( 7 ). For this reason, we investigated the expression of Caveolin-1 and GATA-3 in canine UC to assess their expression patterns and associate them with clinicopathological findings.…”
Section: Discussionmentioning
confidence: 99%
“…Gambim et al ( 7 ) performed a meta-analysis of literature on biomarkers for canine UC and demonstrated a lack of markers for this tumor subtype. Previous studies that investigated biomarkers have usually described the marker expression pattern with no association with clinical and pathological factors ( 8 ).…”
Section: Introductionmentioning
confidence: 99%
“…Previous studies that investigated biomarkers have usually described the marker expression pattern with no association with clinical and pathological factors ( 8 ). Therefore, little is known about factors associated with UC aggressiveness, progression, and invasion ( 7 ). Gambim et al ( 7 ) also found previous studies with transcriptomic data and performed in silico analysis to identify potential biomarkers for canine UC.…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, little is known about factors associated with UC aggressiveness, progression, and invasion ( 7 ). Gambim et al ( 7 ) also found previous studies with transcriptomic data and performed in silico analysis to identify potential biomarkers for canine UC. Among these biomarkers, Caveolin-1 and GATA-binding protein 3 (GATA-3) were identified as promising markers of tumor aggressiveness.…”
The bladder urothelial carcinoma (UC) represents ~2% of malignant neoplasms in dogs and is a therapeutic challenge in veterinary medicine. Although it is considered the most common bladder cancer in dogs, few previous studies have investigated different markers that correlate with clinical and pathological parameters. Therefore, this study aimed to evaluate Caveolin-1, GATA-3, and Ki67 immunostaining in canine UC samples to evaluate their correlations with histopathological variables. Thirty tumor samples were obtained, and Caveolin-1, GATA-3, and Ki67 expression was assessed by immunohistochemistry and associated with pathological factors by univariate and multivariate analyses. Among the histopathological findings, lymphatic invasion was identified in 53.33% of the tumors, and the mean mitotic count (MC) was 31.82 ± 26.26. Caveolin-1 showed mild-to-high cytoplasmic expression in neoplastic cells, whereas GATA-3 showed mild-to-high nuclear expression. The Ki67 expression revealed a mean of 24.14 ± 16.88% positive cells. In the univariate analysis, no association was found between each marker and the pathological findings. On the other hand, in multivariate analysis, we identified a positive correlation between GATA-3 and MC and a negative correlation between Caveolin-1 and MC. Moreover, lymphatic invasion was positively correlated with histological type and grade, and negatively correlated with MC. In addition, the histological type was positively correlated with the histological grade. Overall, our results indicate that Caveolin-1 and GATA-3 expression could be promising markers for bladder UC aggressiveness.
“…Canine UC is known for its increased invasiveness at the time of diagnosis and is an important model for muscle-invasive diseases in humans ( 1 , 4 ). However, despite the difficulties associated with the treatment of this tumor type in dogs, most studies related to biomarkers for bladder UC in veterinary medicine analyze isolated molecules without assessing their prognostic value or association with other variables ( 7 ). For this reason, we investigated the expression of Caveolin-1 and GATA-3 in canine UC to assess their expression patterns and associate them with clinicopathological findings.…”
Section: Discussionmentioning
confidence: 99%
“…Gambim et al ( 7 ) performed a meta-analysis of literature on biomarkers for canine UC and demonstrated a lack of markers for this tumor subtype. Previous studies that investigated biomarkers have usually described the marker expression pattern with no association with clinical and pathological factors ( 8 ).…”
Section: Introductionmentioning
confidence: 99%
“…Previous studies that investigated biomarkers have usually described the marker expression pattern with no association with clinical and pathological factors ( 8 ). Therefore, little is known about factors associated with UC aggressiveness, progression, and invasion ( 7 ). Gambim et al ( 7 ) also found previous studies with transcriptomic data and performed in silico analysis to identify potential biomarkers for canine UC.…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, little is known about factors associated with UC aggressiveness, progression, and invasion ( 7 ). Gambim et al ( 7 ) also found previous studies with transcriptomic data and performed in silico analysis to identify potential biomarkers for canine UC. Among these biomarkers, Caveolin-1 and GATA-binding protein 3 (GATA-3) were identified as promising markers of tumor aggressiveness.…”
The bladder urothelial carcinoma (UC) represents ~2% of malignant neoplasms in dogs and is a therapeutic challenge in veterinary medicine. Although it is considered the most common bladder cancer in dogs, few previous studies have investigated different markers that correlate with clinical and pathological parameters. Therefore, this study aimed to evaluate Caveolin-1, GATA-3, and Ki67 immunostaining in canine UC samples to evaluate their correlations with histopathological variables. Thirty tumor samples were obtained, and Caveolin-1, GATA-3, and Ki67 expression was assessed by immunohistochemistry and associated with pathological factors by univariate and multivariate analyses. Among the histopathological findings, lymphatic invasion was identified in 53.33% of the tumors, and the mean mitotic count (MC) was 31.82 ± 26.26. Caveolin-1 showed mild-to-high cytoplasmic expression in neoplastic cells, whereas GATA-3 showed mild-to-high nuclear expression. The Ki67 expression revealed a mean of 24.14 ± 16.88% positive cells. In the univariate analysis, no association was found between each marker and the pathological findings. On the other hand, in multivariate analysis, we identified a positive correlation between GATA-3 and MC and a negative correlation between Caveolin-1 and MC. Moreover, lymphatic invasion was positively correlated with histological type and grade, and negatively correlated with MC. In addition, the histological type was positively correlated with the histological grade. Overall, our results indicate that Caveolin-1 and GATA-3 expression could be promising markers for bladder UC aggressiveness.
“…Urothelial carcinomas (UC) are the most common genitourinary tumors in dogs and closely mimic the muscle-invasive phenotype that is seen in humans [ 33 , 36 , 161 ] ( Figure 6 ). The BRAF V595E mutation is seen in roughly 85% of canine patients with UC, which has prompted recent investigation into the efficacy of vemurafenib in dogs [ 162 , 163 , 164 , 165 , 166 ]. Several groups have documented the immune landscape and mRNA expression of canine UC, revealing its utility as a relevant translational model [ 37 , 38 , 167 , 168 , 169 ].…”
Despite the important role of preclinical experiments to characterize tumor biology and molecular pathways, there are ongoing challenges to model the tumor microenvironment, specifically the dynamic interactions between tumor cells and immune infiltrates. Comprehensive models of host-tumor immune interactions will enhance the development of emerging treatment strategies, such as immunotherapies. Although in vitro and murine models are important for the early modelling of cancer and treatment-response mechanisms, comparative research studies involving veterinary oncology may bridge the translational pathway to human studies. The natural progression of several malignancies in animals exhibits similar pathogenesis to human cancers, and previous studies have shown a relevant and evaluable immune system. Veterinary oncologists working alongside oncologists and cancer researchers have the potential to advance discovery. Understanding the host-tumor-immune interactions can accelerate drug and biomarker discovery in a clinically relevant setting. This review presents discoveries in comparative immuno-oncology and implications to cancer therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.